FY25 R&D Tax Incentive received
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Entropy Neurodynamics Limited has announced the receipt of a significant R&D Tax Incentive refund from the Australian Government for the financial year period related to its research activities. The company plans to use the proceeds from this refund to further advance its clinical development programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Australian Patent Secures TRP 8803 Platform to 2042
- Quarterly Activities Report and Appendix 4C
- First TRP-8803 BED patient shows broad clinical improvement
Later from Entropy Neurodynamics
- TRP-8803 delivers repeatable, high-intensity effect
- TRP 8802 delivers 75% breakthrough response in IBS
- Entropy files new US patent for IBS program
- Entropy completes Cohort 1 dosing in BED trial
- DSMB Clears TRP 8803 to Advance to Cohort 2
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics